| Society of Integrative Medicine on Oral Maxillofacial Oncology of China Anti-Cancer Association,Society of Minimally Invasive Therapy of China Anti-Cancer Association.Expert consensus on iodine-125 interstitial brachytherapy for parotid gland cancer (2023 edition)[J].Chinese Journal of Radiological Medicine and Protection,2023,43(11):851-857 |
| Expert consensus on iodine-125 interstitial brachytherapy for parotid gland cancer (2023 edition) |
| Received:August 03, 2023 |
| DOI：10.3760/cma.j.cn112271-20230803-00030 |
| KeyWords:Radioactive iodine-125 seeds Parotid gland cancer Expert consensus |
| FundProject: |
|
| Hits: 776 |
| Download times: 319 |
| Abstract:: |
| Iodine-125 (125I) interstitial brachytherapy, a primary method for treating parotid gland cancer, allows for a high dose to the target area while protecting surrounding normal tissues. The efficacy of radioactive 125I seeds is closely related to the dose and accuracy. However, there is a lack of specifications for the application of radioactive 125I seeds in the treatment of parotid gland cancer presently, with relevant criteria differing greatly between medical centers. To further standardize the process of 125I interstitial brachytherapy for parotid gland cancer, this expert consensus was achieved through repeated discussions and modifications of many Chinese experts in the field of brachytherapy. This consensus, consisting of the normative recommendations on the indications, contraindications, treatment parameters, operation process, technical specifications, radiation protection, adverse reactions, and follow-up of the brachytherapy, can be used as a reference for clinical practice. |
| HTML View Full Text View/Add Comment Download reader |
| Close |
|
|
|
